Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


15.10.2018

1 AJNR Am J Neuroradiol
1 BMC Neurol
1 Brain
2 J Neurol
5 Mult Scler
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJNR Am J Neuroradiol

  1. MATTAY RR, Davtyan K, Bilello M, Mamourian AC, et al
    Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis.
    AJNR Am J Neuroradiol. 2018 Oct 4. pii: ajnr.A5828. doi: 10.3174/ajnr.A5828.
    PubMed     Text format     Abstract available


    BMC Neurol

  2. MELENDEZ-TORRES GJ, Armoiry X, Court R, Patterson J, et al
    Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages.
    BMC Neurol. 2018;18:162.
    PubMed     Text format     Abstract available


    Brain

  3. CALDITO NG, Saidha S, Sotirchos ES, Dewey BE, et al
    Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.
    Brain. 2018 Oct 11. pii: 5127751. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Neurol

  4. MCLAUGHLIN L, Clarke L, Khalilidehkordi E, Butzkueven H, et al
    Vitamin D for the treatment of multiple sclerosis: a meta-analysis.
    J Neurol. 2018 Oct 3. pii: 10.1007/s00415-018-9074.
    PubMed     Text format     Abstract available

  5. HUHN K, Bayas A, Doerck S, Frank B, et al
    Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    J Neurol. 2018 Apr 25. pii: 10.1007/s00415-018-8871.
    PubMed     Text format     Abstract available


    Mult Scler

  6. VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
    Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
    Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
    PubMed     Text format    

  7. KALB R, Beier M, Benedict RH, Charvet L, et al
    Recommendations for cognitive screening and management in multiple sclerosis care.
    Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
    PubMed     Text format     Abstract available

  8. CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
    Age is a critical determinant in recovery from multiple sclerosis relapses.
    Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
    PubMed     Text format     Abstract available

  9. WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
    Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
    PubMed     Text format     Abstract available

  10. GRAF J, Ringelstein M, Lepka K, Schaller J, et al
    Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
    Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
    PubMed     Text format     Abstract available


    PLoS One

  11. GRACIA F, Larreategui M, Rodriguez G, Benzadon A, et al
    Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life.
    PLoS One. 2018;13:e0204681.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: